Compare DLY & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLY | PACB |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.8M | 715.5M |
| IPO Year | N/A | 2010 |
| Metric | DLY | PACB |
|---|---|---|
| Price | $14.59 | $1.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 215.9K | ★ 6.3M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $154,584,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $11.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.26 | $0.85 |
| 52 Week High | $15.95 | $2.73 |
| Indicator | DLY | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 45.20 |
| Support Level | $14.47 | $1.67 |
| Resistance Level | $14.59 | $1.89 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 60.39 | 25.12 |
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.